Clinical trial
Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney…
NCT00286156 · The Cleveland Clinic, Other · Completed
Key facts
| NCT number | NCT00286156 |
|---|---|
| Title | Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
| Official title | Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease |
| Lead sponsor | The Cleveland Clinic, Other |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Polycystic Kidney Diseases |
| Intervention type | Drug |
| Interventions | Rapamune |
| Enrollment | 30 |
| Start date | Oct 1, 2006 |
| Primary completion | Mar 1, 2012 |
| Completion | Dec 1, 2014 |
| First posted | Feb 3, 2006 |
| Last update posted | Apr 6, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: